GlassScriptPhysician profile
Stacey Anderson
NPI 1427089333
$1,986.07
in general payments reported to CMS, 2019-2025
26 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $221 · 2022: $505 · 2023: $903 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $785.09 | 2021-2025 | |
| Lilly USA, LLC | $155.08 | 2021-2023 | Mounjaro, Emgality, Jardiance |
| Novo Nordisk INC | $128.85 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $112.72 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.37 | 2022-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $62.89 | 2021 | |
| Amgen INC. | $57.96 | 2021-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $52.89 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Biohaven Pharmaceutical Holding Company LTD. | $51.74 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $47.93 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $41.93 | 2022-2023 | Trintellix |
| Pfizer INC. | $41.20 | 2021-2023 | |
| Organon LLC | $38.62 | 2022-2023 | Nexplanon |
| Ibsa Pharma INC. | $38.61 | 2022-2023 | Tirosint, Licart |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.39 | 2023 | Xifaxan |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $34.69 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $33.47 | 2022 | |
| Mannkind Corporation | $31.80 | 2023 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $31.15 | 2021-2023 | Farxiga |
| Covis Pharma Gmbh | $30.06 | 2022 | |
| Axsome Therapeutics, INC. | $22.10 | 2025 | Symbravo |
| Esperion Therapeutics, INC. | $18.73 | 2021 | |
| Gilead Sciences, INC. | $17.88 | 2025 | |
| Astellas Pharma US INC | $14.83 | 2023 | Myrbetriq |
| Biohaven Pharmaceuticals, INC. | $13.80 | 2021 | |
| Endogastric Solutions, INC | $9.29 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.